Instrument Inactif

Communiqués Synthorx, Inc.

Actions

US87167A1034

Communiqués

23/01/20	SYNTHORX, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
21/01/20	Sanofi : - Hart-Scott-Rodino waiting period expires for Sanofi :'s acquisition of Synthorx	AQ
10/12/19	Sanofi : to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion	AQ
09/12/19	Synthorx : Drug giant Sanofi to buy U.S. biotech firm Synthorx for $2.5B	AQ
09/12/19	SYNTHORX ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of THOR and Encourages Investors to Contact the Firm	PR
09/12/19	SYNTHORX, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/11/19	Synthorx to Present at Upcoming Investor Conferences	GL
05/11/19	Synthorx Reports Third Quarter Financial Results	GL
05/11/19	Synthorx to Present THOR-809 Data at the American College of Rheumatology (ACR) Annual Meeting	GL
29/10/19	Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting	GL
29/08/19	Synthorx to Present at H.C. Wainwright 21st Annual Global Investment Conference	GL
01/08/19	Synthorx Reports Second Quarter Financial Results	GL
29/05/19	Synthorx to Present at Jefferies 2019 Healthcare Conference	GL
15/05/19	Synthorx to Present at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting	GL
30/04/19	Synthorx Reports First Quarter Financial Results	GL
19/03/19	Synthorx to Present at the American Association of Cancer Research (AACR) Annual Meeting 2019	GL
12/03/19	Synthorx to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy	GL
21/02/19	Synthorx to Present at the 8th Annual SVB Leerink Global Healthcare Conference	GL
20/12/18	Synthorx Appoints Andrew Powell, J.D., to its Board of Directors	GL
12/12/18	Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	GL